Title:
BRCA媒介性疾患における使用のための、プロゲステロン受容体拮抗薬と、ルテインホルモン放出ホルモン作動薬および拮抗薬との組み合わせ
Document Type and Number:
Japanese Patent JP2010524996
Kind Code:
A
Abstract:
The present invention relates to the combination of the progesterone-receptor antagonist 11beta-(4-acetylphenyl)-17beta-hydroxy-17alpha-(1,1,2,2,2-pentafluoroethyl)-estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue thereof, together with at least one lutein-hormone-releasing hormone agonist or antagonist and to the use of said combination for the prophylaxis and treatment of BRCA1- or BRCA2-mediated diseases. Lutein-hormone-releasing hormone agonists and antagonists, which can be combined together with the compound 11beta-(4-acetylphenyl)-17beta-hydroxy-17alpha-(1,1,2,2,2 pentafluoroethyl)-estra-4,9-dien-3-one are for example gonadorelin, goserelin, triptorelin, buserelin, nafarelin, deslorelin, histrelin, antide, ramorelix, cetrorelix, antarelix, ORG30850, abarelix, ganirelix and leuprolin.
Inventors:
Hoffman, Jens
Cole, Daniel
Cole, Daniel
Application Number:
JP2010504549A
Publication Date:
July 22, 2010
Filing Date:
April 21, 2008
Export Citation:
Assignee:
Bayer Schering Pharma Aktiengesellschaft
International Classes:
A61K31/567; A61K45/00; A61P5/24; A61P5/36; A61P15/00; A61P35/00; A61P43/00; C07J1/00
Attorney, Agent or Firm:
Atsushi Aoki
Takashi Ishida
Fukumoto product
Tetsuji Koga
Yoichi Watanabe
Ryotaro Takei
Takahide Sasaki
Takashi Ishida
Fukumoto product
Tetsuji Koga
Yoichi Watanabe
Ryotaro Takei
Takahide Sasaki